Direct control of CAR T cells through small molecule-regulated antibodies
Many next-generation antibody therapeutics have enhanced potency but the risk of adverse events. Here the authors develop a conditionally activated, single-module CAR.
Enregistré dans:
Auteurs principaux: | Spencer Park, Edward Pascua, Kevin C. Lindquist, Christopher Kimberlin, Xiaodi Deng, Yvonne S. L. Mak, Zea Melton, Theodore O. Johnson, Regina Lin, Bijan Boldajipour, Robert T. Abraham, Jaume Pons, Barbra Johnson Sasu, Thomas J. Van Blarcom, Javier Chaparro-Riggers |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Nature Portfolio
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/a6c74f8c5d424b06a2dbc5aa3382a4ec |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity
par: Shahram Salek-Ardakani, et autres
Publié: (2021) -
Germline-encoded neutralization of a Staphylococcus aureus virulence factor by the human antibody repertoire
par: Yik Andy Yeung, et autres
Publié: (2016) -
Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies
par: Sergey Kulemzin, et autres
Publié: (2021) - Car and driver
-
CAR T-CELL
par: Francesco Saglio
Publié: (2021)